| Name | Hikma Pharmaceuticals |
|---|---|
| Epic | HIK |
| Isin | GB00B0LCW083 |
| Index | UK100 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1,964.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £4,357.85 | Debt ratio | n/a |
| Shares in issue | 221.89 | Debt-to-equity ratio | n/a |
| P/E ratio | 10 | Assets / equity ratio | n/a |
| Total dividends per share | 72.00¢ | Price to book value | n/a |
| Dividend yield | 3.2 | ROCE | 15.82 |
| Dividend cover | 3.1 | EPS growth | 23 |
| Earning per share | 86 | 52-week high / low | 1,722.00p / 2,127.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Final | 2024-03-21 | 2024-05-03 | 47.00¢ |
| Interim | 2023-08-10 | 2023-09-15 | 25.00¢ |
| Final | 2023-03-23 | 2023-05-05 | 37.00¢ |
| Interim | 2022-08-18 | 2022-09-20 | 19.00¢ |
| Final | 2022-03-17 | 2022-04-28 | 36.00¢ |
| Interim | 2021-08-19 | 2021-09-20 | 18.00¢ |
| Final | 2021-03-18 | 2021-04-26 | 34.00¢ |
| Interim | 2020-08-20 | 2020-09-21 | 16.00¢ |
| Final | 2020-03-19 | 2020-05-07 | 30.00¢ |
| Company name | Hikma Pharmaceuticals |
|---|---|
| Address | 1 New Burlington Place, London,United Kingdom, W1S 2HR |
| Telephone | +44 (0)20 7399 2760 |
| Website | http://www.hikma.com |
| Director | Position |
|---|---|
| Mr Riad Mishlawi | CEO |
| Mr Ali Al-Husry | Non-Executive Director |
| Mr Said Darwazah | Executive Chairman |
| Ms Mary (Nina) Henderson | Independent Non-Executive Director |
| Mr Douglas Hurt | Independent Non-Executive Director |
| Mr John J. Castellani | Independent Non-Executive Director |
| Ms Deneen Vojta | Independent Non-Executive Director |
| Ms Laura Balan Balan | Independent Non-Executive Director |
| Mrs Cynthia Schwalm | Independent Non-Executive Director |
| Ms Victoria Hull | Independent Non-Executive Director |
| Mr Mazen Darwazah | Executive Vice Chairman |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 1100 | 1124 | 892 |
| Investments and other non-current assets | 10 | 10 | 10 |
| Total non-current assets | 2580 | 2472 | 2278 |
| Inventory / work in progress | 891 | 776 | 695 |
| Trade and other receivables | 873 | 841 | 876 |
| Cash and equivalents | 205 | 270 | 426 |
| Other current assets and asset held for resale | 131 | 112 | 97 |
| Total of all assets | 4680 | 4471 | 4372 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 1339 | 1077 | 1016 |
| Long term liabilities | 1132 | 1246 | 889 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 2471 | 2323 | 1905 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 2209 | 2148 | 2467 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 40 | 40 | 42 |
| Minority interests | 11 | 13 | 14 |
| Retained earnings | 2158 | 2092 | 2189 |
| Share premium account | 282 | 282 | 282 |
| Total equity | 2209 | 2148 | 2467 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 367 | 282 | 582 |
| Pre-tax profit | 281 | 233 | 544 |